Exscientia Plc (EXAI) has released an update.
Confident Investing Starts Here:
- Easily unpack a company's performance with TipRanks' new KPI Data for smart investment decisions
- Receive undervalued, market resilient stocks right to your inbox with TipRanks' Smart Value Newsletter
Exscientia Plc has announced its acquisition of full rights to a promising CDK7 inhibitor, GTAEXS617, from GT Apeiron, with phase 1/2 clinical trial data expected in the latter half of 2024 and a combination study to follow soon after. The drug, designed using AI, shows potential in treating various advanced solid tumors and could significantly improve treatment options for cancer patients. Exscientia’s financial commitment includes an upfront payment and royalties, maintaining a solid cash runway projected to last into 2027.
For further insights into EXAI stock, check out TipRanks’ Stock Analysis page.
Trending Articles:
Looking for a trading platform? Check out TipRanks' Best Online Brokers guide, and find the ideal broker for your trades.
Report an Issue